Biomarkers in the Prediction of Cancer-Related Cognitive Impairment: Implications within Supportive Care
Year: 2023
Type: article
Abstract: Patients and survivors of cancer may develop cognitive impairment pre-, intra-, and posttreatment, which is a phenomenon known as cancer-related cognitive impairment (CRCI) or chemobrain.CRCI can adversely affect the quality of life in patients and survivors of cancer.Several factors are associated with CRCI, and the proposed CRCI mechanisms include oxidative stress, dysregulation of inflammatory cytokines, genetic susceptibility, hormone deficiencies and/or psychological distress.Over the past 15 years (2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016)(2017)(2018)(2019)(2020)(2021)(2022)(2023), our Singapore-and United States-based research team has conducted numerous human studies to evaluate the underlying mechanisms of CRCI through biomarker discovery and validation.Hence, this narrative review aims to elucidate the association between peripheral biomarkers evaluated in our past studies and cognitive function among non-CNS cancer survivors.In summary, plasma levels of brain-derived neurotrophic factor, inflammatory cytokines, and dynamin-1 in plasma extracellular vesicles have shown promising roles in CRCI pathophysiology.These findings indicate that further investigations are required to explore their potential to translate observational results into experimental therapeutics.
Source: Research in Clinical Pharmacy
DOI: 10.59931/rcp.23.008
Authors: Alexandre Chan, Ding Quan Ng, Rukh Yusuf, Wenjia Lu
Institution: University of California, Irvine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4382894900